---
title: "Cost-effectiveness of rivaroxaban plus aspirin in COMPASS: a Scandinavian lifetime analysis"
id: "pubmed-42700109"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42700109"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42700109/"
doi: "10.1080/14017431.2026.2728343"
published_at: "2026-09-17T12:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Cost-effectiveness of rivaroxaban plus aspirin in COMPASS: a Scandinavian lifetime analysis
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42700109
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42700109/)
- **DOI:** [10.1080/14017431.2026.2728343](https://doi.org/10.1080%2F14017431.2026.2728343)
- **Published At:** 2026-09-17T12:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- The COMPASS trial compared **rivaroxaban** 2.5 mg twice daily plus **aspirin** 100 mg daily versus aspirin 100 mg daily alone in patients with coronary or peripheral artery disease. - The study reported here projects lifetime cost-effectiveness from a Scandinavian perspective using data from COMPASS as the clinical input. - A two-state Markov model was used to estimate mean lifetime costs (in USD) and quality-adjusted life-years (**QALYs**); US mortality data were applied in the model. - Subgroup analyses and sensitivity analyses were performed to explore uncertainty and variability in results. - Over a lifetime horizon, adding rivaroxaban to aspirin resulted in lower costs compared with aspirin alone, with a reported cost difference of -$3,791 USD (also reported in regional currencies: -23,675 DKK / -27,410 NOK / -29,200 SEK). - The combination therapy produced an incremental gain of 1.17 QALYs versus aspirin alone. - Based on modeled lifetime costs and QALYs, rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily was judged to be a dominant strategy (better outcomes and lower costs) from a Scandinavian perspective in COMPASS participants. - Keywords and indexed MeSH terms include **rivaroxaban**, anticoagulation, coronary artery disease, peripheral artery disease, aspirin, cost-effectiveness, cost savings, and cost–benefit/analysis.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42700109/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42700109%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42700109/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42700109/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42700109/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/c24ab723-7c80-48cd-9c68-022ded852586/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42700109/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42700109/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42700109/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42700109%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42700109%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42700109/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42700109/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42700109/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42700109/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Full text links [![Atypon full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--www.tandfonline.com-pb-assets-tandf-logos-tf_pubmed_OA_fulltext_icon.png) Atypon ](https://www.tandfonline.com/doi/10.1080/14017431.2026.2728343?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed "See full text options at Atypon") [ Full text links ](https://pubmed.ncbi.nlm.nih.gov/42700109/) ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42700109/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42700109/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42700109/#abstract) * [Similar articles](https://pubmed.ncbi.nlm.nih.gov/42700109/#similar) * [ Publication types ](https://pubmed.ncbi.nlm.nih.gov/42700109/#publication-types) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42700109/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42700109/#substances) * [Related information](https://pubmed.ncbi.nlm.nih.gov/42700109/#related-links) * [ LinkOut - more resources ](https://pubmed.ncbi.nlm.nih.gov/42700109/#linkout) Title & authors Abstract Similar articles Publication types MeSH terms Substances Related information LinkOut - more resources Comparative Study Scand Cardiovasc J Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Scand+Cardiovasc+J%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Scand+Cardiovasc+J%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42700109/) . 2026 Dec;60(1):2728343. doi: 10.1080/14017431.2026.2728343. Epub 2026 Sep 17. # A Scandinavian perspective of the projected lifetime cost-effectiveness of rivaroxaban plus aspirin in the COMPASS trial [Andre Lamy](https://pubmed.ncbi.nlm.nih.gov/?term=Lamy+A&cauthor_id=42700109)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42700109/#full-view-affiliation-1 "Population Health Research Institute, McMaster University, Hamilton, Canada."), [Lars Ryden](https://pubmed.ncbi.nlm.nih.gov/?term=Ryden+L&cauthor_id=42700109)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42700109/#full-view-affiliation-2 "Department of Medicine K2, Karolinska Institutet, Stockholm, Sweden."), [Wesley Tong](https://pubmed.ncbi.nlm.nih.gov/?term=Tong+W&cauthor_id=42700109)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42700109/#full-view-affiliation-1 "Population Health Research Institute, McMaster University, Hamilton, Canada."), [Fei Yuan](https://pubmed.ncbi.nlm.nih.gov/?term=Yuan+F&cauthor_id=42700109)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42700109/#full-view-affiliation-1 "Population Health Research Institute, McMaster University, Hamilton, Canada.")[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42700109/#full-view-affiliation-3 "Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada."), [John W Eikelboom](https://pubmed.ncbi.nlm.nih.gov/?term=Eikelboom+JW&cauthor_id=42700109)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42700109/#full-view-affiliation-1 "Population Health Research Institute, McMaster University, Hamilton, Canada.")[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42700109/#full-view-affiliation-4 "Department of Medicine, McMaster University, Hamilton, Canada."); [COMPASS Investigators](https://pubmed.ncbi.nlm.nih.gov/?term=COMPASS+Investigators%5BCorporate+Author%5D) Affiliations Expand ### Affiliations * 1 Population Health Research Institute, McMaster University, Hamilton, Canada. * 2 Department of Medicine K2, Karolinska Institutet, Stockholm, Sweden. * 3 Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada. * 4 Department of Medicine, McMaster University, Hamilton, Canada. * PMID: **42700109** * DOI: [ 10.1080/14017431.2026.2728343 ](https://doi.org/10.1080/14017431.2026.2728343) Free article Item in Clipboard Comparative Study # A Scandinavian perspective of the projected lifetime cost-effectiveness of rivaroxaban plus aspirin in the COMPASS trial Andre Lamy et al. Scand Cardiovasc J. 2026 Dec. Free article Show details Display options Display options Format Abstract PubMed PMID Scand Cardiovasc J Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Scand+Cardiovasc+J%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Scand+Cardiovasc+J%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42700109/) . 2026 Dec;60(1):2728343. doi: 10.1080/14017431.2026.2728343. Epub 2026 Sep 17. ### Authors [Andre Lamy](https://pubmed.ncbi.nlm.nih.gov/?term=Lamy+A&cauthor_id=42700109)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42700109/#short-view-affiliation-1 "Population Health Research Institute, McMaster University, Hamilton, Canada."), [Lars Ryden](https://pubmed.ncbi.nlm.nih.gov/?term=Ryden+L&cauthor_id=42700109)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42700109/#short-view-affiliation-2 "Department of Medicine K2, Karolinska Institutet, Stockholm, Sweden."), [Wesley Tong](https://pubmed.ncbi.nlm.nih.gov/?term=Tong+W&cauthor_id=42700109)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42700109/#short-view-affiliation-1 "Population Health Research Institute, McMaster University, Hamilton, Canada."), [Fei Yuan](https://pubmed.ncbi.nlm.nih.gov/?term=Yuan+F&cauthor_id=42700109)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42700109/#short-view-affiliation-1 "Population Health Research Institute, McMaster University, Hamilton, Canada.")[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42700109/#short-view-affiliation-3 "Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada."), [John W Eikelboom](https://pubmed.ncbi.nlm.nih.gov/?term=Eikelboom+JW&cauthor_id=42700109)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42700109/#short-view-affiliation-1 "Population Health Research Institute, McMaster University, Hamilton, Canada.")[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42700109/#short-view-affiliation-4 "Department of Medicine, McMaster University, Hamilton, Canada."); [COMPASS Investigators](https://pubmed.ncbi.nlm.nih.gov/?term=COMPASS+Investigators%5BCorporate+Author%5D) ### Affiliations * 1 Population Health Research Institute, McMaster University, Hamilton, Canada. * 2 Department of Medicine K2, Karolinska Institutet, Stockholm, Sweden. * 3 Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada. * 4 Department of Medicine, McMaster University, Hamilton, Canada. * PMID: **42700109** * DOI: [ 10.1080/14017431.2026.2728343 ](https://doi.org/10.1080/14017431.2026.2728343) Item in Clipboard Full text links Cite Display options Display options Format Abstract PubMed PMID ## Abstract _Objectives_. Rivaroxaban 2.5 mg twice daily with aspirin 100 mg daily was superior to aspirin 100 mg daily in the COMPASS trial but the cost-effectiveness in Scandinavia is unknown. _Design_. Mean lifetime costs (USDs) and quality-adjusted life-years were determined from a Scandinavian perspective using a 2-state Markov model with US mortality data. Subgroup and sensitivity analyses were performed. _Results_. Over a lifetime adding rivaroxaban to aspirin had lower costs (-$3791USD/-23675DKK/-27410NOK/-29200SEK) and gained 1.17 QALYs versus ASA alone. _Conclusion._ Rivaroxaban 2.5 mg twice daily with aspirin is a dominant strategy compared to aspirin alone in COMPASS participants from a Scandinavian perspective. **Keywords:** Rivaroxaban; anticoagulation; coronary artery disease; cost-effectiveness; peripheral artery disease. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Similar articles * [ Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland. ](https://pubmed.ncbi.nlm.nih.gov/32519113/) Soini E, Virtanen O, Väätäinen S, Briere JB, Bowrin K, Millier A.Soini E, et al.Adv Ther. 2020 Jul;37(7):3348-3369. doi: 10.1007/s12325-020-01398-8. Epub 2020 Jun 9.Adv Ther. 2020.PMID: 32519113Free PMC article. * [ Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease. ](https://pubmed.ncbi.nlm.nih.gov/31807773/) Cowie MR, Lamy A, Levy P, Mealing S, Millier A, Mernagh P, Cristeau O, Bowrin K, Briere JB.Cowie MR, et al.Cardiovasc Res. 2020 Sep 1;116(11):1918-1924. doi: 10.1093/cvr/cvz278.Cardiovasc Res. 2020.PMID: 31807773Free PMC article. * [ Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy. ](https://pubmed.ncbi.nlm.nih.gov/33725323/) Ferrara P, Cortesi PA, Di Laura D, Maggioni AP, Mantovani LG.Ferrara P, et al.Clin Drug Investig. 2021 May;41(5):459-468. doi: 10.1007/s40261-021-01023-8. Epub 2021 Mar 16.Clin Drug Investig. 2021.PMID: 33725323Free PMC article. * [ Cost-effectiveness of rivaroxaban plus aspirin versus aspirin alone in patients with stable coronary artery disease or peripheral artery disease: a systematic review. ](https://pubmed.ncbi.nlm.nih.gov/39714728/) Arabloo J, Rezaei MA, Makhtoumi V, Sadiani ZM, Rezapour A.Arabloo J, et al.Eur J Clin Pharmacol. 2025 Feb;81(2):279-290. doi: 10.1007/s00228-024-03794-3. Epub 2024 Dec 23.Eur J Clin Pharmacol. 2025.PMID: 39714728 * [ Rivaroxaban versus Clopidogrel for Peripheral Artery Disease: A Clinico-Economic Approach of the COMPASS Trial. ](https://pubmed.ncbi.nlm.nih.gov/30621559/) Tsilimigras DI, Moris D, Karaolanis G, Kakkos SK, Filis K, Sigala F.Tsilimigras DI, et al.Curr Pharm Des. 2018;24(38):4516-4517. doi: 10.2174/1381612825666190101100832.Curr Pharm Des. 2018.PMID: 30621559Review. [ See all similar articles ](https://pubmed.ncbi.nlm.nih.gov/?linkname=pubmed_pubmed&from_uid=42700109) ## Publication types * Comparative Study Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Comparative+Study%22%5Bpt%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Comparative+Study) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42700109/) ## MeSH terms * Aged Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Aged%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Aged) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42700109/) * Aspirin* / administration & dosage Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Aspirin%2Fadministration+and+dosage%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Aspirin) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42700109/) * Aspirin* / adverse effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Aspirin%2Fadverse+effects%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Aspirin) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42700109/) * Aspirin* / economics Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Aspirin%2Feconomics%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Aspirin) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42700109/) * Cardiovascular Diseases* / diagnosis Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cardiovascular+Diseases%2Fdiagnosis%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Cardiovascular+Diseases) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42700109/) * Cardiovascular Diseases* / economics Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cardiovascular+Diseases%2Feconomics%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Cardiovascular+Diseases) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42700109/) * Cardiovascular Diseases* / mortality Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cardiovascular+Diseases%2Fmortality%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Cardiovascular+Diseases) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42700109/) * Cardiovascular Diseases* / prevention & control Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cardiovascular+Diseases%2Fprevention+and+control%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Cardiovascular+Diseases) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42700109/) * Cost Savings Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cost+Savings%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Cost+Savings) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42700109/) * Cost-Benefit Analysis Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cost-Benefit+Analysis%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Cost-Benefit+Analysis) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42700109/) * Cost-Effectiveness Analysis Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cost-Effectiveness+Analysis%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Cost-Effectiveness+Analysis) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42700109/) * Drug Administration Schedule Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Drug+Administration+Schedule%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Drug+Administration+Schedule) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42700109/) * Drug Costs* Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Drug+Costs%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Drug+Costs) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42700109/) * Drug Therapy, Combination Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Drug+Therapy%2C+Combination%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Drug+Therapy%2C+Combination) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42700109/) * Factor Xa Inhibitors* / administration & dosage Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Factor+Xa+Inhibitors%2Fadministration+and+dosage%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/
## Related Clinical Research

- [Optimal Antithrombotic Therapy for Peripheral Artery Disease: A Systematic Review and Network Meta‐Analysis](https://medichelpline.com/clinical-feed/journal-of-the-american-heart-association-21-optimal-antithrombotic-therapy-for-peripheral-artery-disease-a-systematic.md)
- [NOAC monotherapy vs NOAC+clopidogrel by age in AF patients with drug-eluting stents](https://medichelpline.com/clinical-feed/pubmed-42546025.md) (DOI: 10.1093/ageing/afag224)
- [Pulmonary artery growth after PDA stent versus modified Blalock–Taussig shunt in ductal-dependent](https://medichelpline.com/clinical-feed/plos-one-20-comparative-outcomes-of-pulmonary-artery-changes-in-ductal-patency-dependent.md)
- [Heparin-induced thrombocytopenia during therapeutic plasma exchange in neuromyelitis optica: singl](https://medichelpline.com/clinical-feed/frontiers-in-immunology-17-case-report-confirmed-and-suspected-heparin-induced-thrombocytopenia-during.md)
- [Low‑dose ticagrelor plus aspirin versus clopidogrel plus aspirin to prevent early neurological det](https://medichelpline.com/clinical-feed/pubmed-42704480.md) (DOI: 10.1007/s00415-026-14094-4)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.